Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. De novo development of small cyclic peptides that are orally bioavailable
 
research article

De novo development of small cyclic peptides that are orally bioavailable

Merz, Manuel Leonardo  
•
Habeshian, Sevan  
•
Li, Bo  
Show more
December 28, 2023
Nature Chemical Biology

Cyclic peptides can bind challenging disease targets with high affinity and specificity, offering enormous opportunities for addressing unmet medical needs. However, as with biological drugs, most cyclic peptides cannot be applied orally because they are rapidly digested and/or display low absorption in the gastrointestinal tract, hampering their development as therapeutics. In this study, we developed a combinatorial synthesis and screening approach based on sequential cyclization and one-pot peptide acylation and screening, with the possibility of simultaneously interrogating activity and permeability. In a proof of concept, we synthesized a library of 8,448 cyclic peptides and screened them against the disease target thrombin. Our workflow allowed multiple iterative cycles of library synthesis and yielded cyclic peptides with nanomolar affinities, high stabilities and an oral bioavailability (%F) as high as 18% in rats. This method for generating orally available peptides is general and provides a promising push toward unlocking the full potential of peptides as therapeutics.|Cyclic peptides show promise for modulating difficult disease targets; however, they often cannot be administered orally. The authors developed a method to synthesize and screen large libraries of small cyclic peptides while enabling the simultaneous interrogation of activity and permeability. This approach was applied to the disease target thrombin to discover peptides with high affinity, stability and oral bioavailability of up to 18% in rats.

  • Files
  • Details
  • Metrics
Type
research article
DOI
10.1038/s41589-023-01496-y
Web of Science ID

WOS:001133223600001

Author(s)
Merz, Manuel Leonardo  
Habeshian, Sevan  
Li, Bo  
David, Jean-Alexandre G. L.
Nielsen, Alexander Lund  
Ji, Xinjian  
Il Khwildy, Khaled  
Benitez, Maury M. Duany  
Phothirath, Phoukham  
Heinis, Christian  
Date Issued

2023-12-28

Published in
Nature Chemical Biology
Subjects

Life Sciences & Biomedicine

•

Drug Discovery

•

Delivery

•

Design

Editorial or Peer reviewed

REVIEWED

Written at

EPFL

EPFL units
LPPT  
CPG  
FunderGrant Number

Schweizerischer Nationalfonds zur Frderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)

192368

Swiss National Science Foundation

101020521-TARGET

European Research Council under the European Union

Available on Infoscience
February 20, 2024
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/204857
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés